Novo Nordisk A/S
Trump drops Biden’s proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters President Donald Trump on Friday dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular but costly GLP-1 treatments such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. But the Centers […]
Read More
The biggest winners and losers in Europe as Trump announces sweeping tariffs
U.S. President Donald Trump stands, after delivering remarks on tariffs, in the Rose Garden at the White House in Washington, D.C., U.S., April 2, 2025. Leah Millis | Reuters Global markets, businesses and long-standing geopolitical relationships were thrown into disarray on Thursday, the day after U.S. President Donald Trump’s tariff policy — and Europe was not […]
Read More
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Boxes of Novo Nordisk’s weight-loss drug Wegovy in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting as the White House moves ahead with plans […]
Read More
These European stocks have the most to lose from Trump’s tariffs
European exporters to the U.S. may face significant headwinds from new tariffs President Donald Trump is expected to unveil Wednesday afternoon . While details remain scarce ahead of a Rose Garden ceremony at 4 p.m. ET, investors have been bracing themselves for broad-based levies on imports. Treasury Secretary Scott Bessent previously called out the “Dirty 15,” […]
Read More
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Signage at the AstraZeneca facility in Gaithersburg, Maryland, US, on Monday, Aug. 26, 2024. Graeme Sloan | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The race to develop more convenient […]
Read More
Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with diabetes and heart disease. The pill lowered the risk of cardiovascular-related death, heart attack and stroke by 14% compared to a placebo after four […]
Read More
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product’
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment. CEO […]
Read More
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Copenhagen, DENMARK — Obesity drug giant Novo Nordisk […]
Read More
CNBC Daily Open: Consumers and CFOs alike are expecting a recession in the U.S.
A Forever 21 store in New York, in March 2025. Yuki Iwamura | Bloomberg | Getty Images The shadow of a U.S. recession is growing longer and darkening the outlook for both consumers and CFOs alike, according to various surveys tracking sentiment in March. That said, Wall Street has risen over the past three days […]
Read More
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. […]
Read More